Aibotics Inc.

What they do

Aibotics promotes the study of psychedelics for treating mental health issues and supports the creation of natural and synthetic molecules for treatment development. It intends to deploy technology from parent company Ehave, Inc. to collect research and clinical data on psychedelic effects. It has a supply agreement with Havn Life Sciences Inc. for naturally derived psilocybin API for testing by universities, researchers and pharmaceutical companies. The company has one subsidiary, Aibotics Therapies Inc., a Florida corporation.

Revenue drivers

• Psilocybin supply and testing activity — The company's only reported revenue was $2,183 in 2025, tied to its Havn Life Sciences psilocybin supply arrangement; revenue was $0 in 2024 and $0 in every quarter of 2025-2026 reported.
• No commercialized product line — No product or segment line generated revenue in the six months ended June 30, 2026 or the three months ended June 30, 2026, both reported at $0.
• Financing inflows, not operations — Cash is generated mainly through financing activities ($529,083 in 2025) rather than sales, with operating cash flow negative $458,240 in 2025.

Recent performance

For the six months ended June 30, 2026, revenue was $0 versus $2,183 in the prior-year period and net loss was $955,073 versus $1,077,546. General and administrative expenses fell 13.3% to $773,126, driven by lower consulting and product development costs. For the three months ended June 30, 2026, net loss was $536,968 and G&A rose 14.7% to $413,663. Full-year 2025 revenue was $2,183 with a net loss of $2,215,751 and operating cash use of $458,240. At June 30, 2026 the company reported total assets of $549,592, total liabilities of $5.2 million and shareholder equity of negative $4.6 million.

Strategy

The company states it promotes psychedelics research and intends to use AI, following an asset acquisition from Philon Labs, to develop products that enhance patient care and streamline medical processes. It has been negotiating with third parties to integrate EHVVF's EEG brain cap technology to capture neurological data during psychedelic-based therapies. It holds a psilocybin API supply agreement with Havn Life Sciences for testing by universities, researchers and pharmaceutical companies. Management expects to meet near-term liquidity needs through existing cash and potential additional financing.

Risks

• No meaningful revenue — Revenue was $2,183 in 2025 and $0 in every reported quarter since, leaving operations dependent on external financing.
• Going-concern liquidity pressure — At December 31, 2025 the company had a working capital deficiency of $4,564,798, current liabilities of $44,834,905 and only $255,940 of cash.
• Negative shareholder equity — At June 30, 2026 total liabilities were $5.2 million against total assets of $549,592, producing shareholder equity of negative $4.6 million.
• Dependence on related and third parties — The business model relies on parent Ehave's technology and a Havn Life Sciences psilocybin supply agreement rather than owned commercial products.

Outlook

Management expects to fund short-term liquidity needs through existing cash and potential additional financing, though it states there can be no assurance such financing will be available on acceptable terms or at all. The company had about $1.1 million of undiscounted indebtedness obligations due within one year as of December 31, 2025. No revenue was reported in the first half of 2026, and the company continues to report net losses while it pursues psychedelics research and technology integration.